Publications – KalVista Pharmaceuticals | KalVista Pharmaceuticals

Patients & Caregivers
- About HAE
Healthcare Professionals
Clinical Trials
Presentations & Publications
Investors & News

About
Science
Pipeline
Careers
- Careers
- Job Openings
Contact

Bringing new developments to Light

Presentations & Publications

We are committed to rigorous science and innovative drug development, and we are excited to share our ongoing progress.

Explore Our
Virtual Medical Booth

Reset all ×
Oral Factor XIIa inhibitor ×
2023 ×

Apply Reset

Topic

Sebetralstat (KVD900) in HAE clinical program (0)
HAE attack journey data (0)
HAE burden of treatment data (0)
Oral Factor XIIa inhibitor (2)

Forum

Medical Meeting (1)
Publication (1)

Year

2024 (1)
2023 (2)
2022 (3)
2021 (1)
2020 (0)
2019 (0)
2018 (0)
2017 (0)
2016 (0)
2015 (0)
2013 (0)
2011 (0)
2010 (0)
2009 (0)
2008 (0)
2007 (0)

Apply Reset

Showing 2 out of 2

Oral FXIIa inhibitor KV998086 suppresses FXIIa and single chain FXII mediated kallikrein kinin system activation

Clermont AC, Murugesan N, Edwards HJ, Lee DK, Bayliss NP, Duckworth EJ, Pethen SJ, Hampton SL, Gailani D, Feener EP

Frontiers in Pharmacology

PB0536: Oral Factor XIIa inhibitor KV998086 protects against FeCl3 induced thrombosis in mice.

Clermont A, Pinckney F, Hill M, Hampton SL, Feener EP

About

Management team

Board of Directors

Science

Pipeline

Oral Factor XIIa Inhibitor

Careers

Contact

KalVista Terms of Use Privacy Policy

© 2024 KalVista Pharmaceuticals. All Rights Reserved.